Gregor Schulz
9Patents
5h-index
24Co-inventors
63Inventor score
Filing activity: Jul 26, 1984 → Dec 7, 2012
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4675287A | Monoclonal antibody directed to human ganglioside GD.sub.2 | Emerging Cross-Sectional Technologies | 42 | Expired |
| US9011864B2 | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates | Chemistry; Metallurgy | 16 | Active |
| US10117932B2 | Uses of immunoconjugates targeting CD138 | Human Necessities | 7 | Active |
| US9289509B2 | Uses of immunoconjugates targeting CD138 | Performing Operations; Transporting | 6 | Active |
| US9221914B2 | Agents targeting CD138 and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US9387261B2 | Immunoconjugates targeting CD138 and uses thereof | Chemistry; Metallurgy | 3 | Active |
| US9512226B2 | Agent for treating disease | Chemistry; Metallurgy | 0 | Active |
| US9550831B2 | Method for treating psoriasis | Chemistry; Metallurgy | 0 | Active |
| US9995733B2 | Agents for treating disease | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.